Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

56.86USD
30 Jan 2015
Change (% chg)

$-0.70 (-1.22%)
Prev Close
$57.56
Open
$57.43
Day's High
$57.77
Day's Low
$56.84
Volume
589,165
Avg. Vol
669,490
52-wk High
$61.90
52-wk Low
$43.33

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $54,385.80
Shares Outstanding(Mil.): 956.55
Dividend: 0.32
Yield (%): 2.35

Financials

  TEVA.N Industry Sector
P/E (TTM): 17.91 39.97 40.64
EPS (TTM): 3.21 -- --
ROI: 7.79 18.85 18.12
ROE: 11.96 19.60 18.97
Search Stocks

BUZZ-India's Cipla surges to record high on generic Nexium supply hopes

** India's Cipla rises as much as 4.8 pct to record high of 710 rupees

27 Jan 2015

FDA approves Teva's generic version of AstraZeneca's Nexium

- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.

27 Jan 2015

UPDATE 1-FDA approves Teva's generic version of AstraZeneca's Nexium

Jan 26 - The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.

27 Jan 2015

FDA approves Teva's generic version of AstraZeneca's Nexium

Jan 26 - The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's Nexium to treat acid reflux, the agency's first generic approval for the drug.

27 Jan 2015

REFILE-BRIEF-Natco Pharma says US Supreme Court remanded case relating to Teva's US patent to Court of Appeals

(Corrects dateline) Jan 21 - Natco Pharma Ltd : * The US supreme court has remanded case relating to Teva's US patent no

21 Jan 2015

U.S. Supreme Court rules for Teva over MS drug patent

WASHINGTON - The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product.

20 Jan 2015

Supreme Court rules for Teva over MS drug patent

WASHINGTON - The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product.

20 Jan 2015

UPDATE 3-U.S. Supreme Court rules for Teva over MS drug patent

WASHINGTON, Jan 20 - The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product.

20 Jan 2015

UPDATE 1-Teva Pharm sees 2015 revenue lower than forecast

TEL AVIV, Dec 11 - Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone.

11 Dec 2014

Teva Pharm sees lower than forecast 2015 revenue

TEL AVIV, Dec 11 - Teva Pharmaceutical Industries , the world's biggest generic drugmaker, forecast 2015 revenue below analysts' expectations and assumes its best-selling multiple sclerosis treatment will face competition in September.

11 Dec 2014

Competitors

  Price Chg
Novartis AG (NOVN.VX) CHF90.15 -0.85
Biogen Idec Inc (BIIB.OQ) $389.16 +35.91

Earnings vs. Estimates

Search Stocks